PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
4.31%
Gross profit growth under 50% of AXSM's 21.76%. Michael Burry would be concerned about a severe competitive disadvantage.
8.25%
EBIT growth above 1.5x AXSM's 4.51%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
8.25%
Operating income growth above 1.5x AXSM's 4.51%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
12.55%
Net income growth above 1.5x AXSM's 7.40%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
15.52%
EPS growth similar to AXSM's 14.29%. Walter Schloss would assume both have parallel share structures and profit trends.
15.52%
Similar diluted EPS growth to AXSM's 14.29%. Walter Schloss might see standard sector or cyclical influences on both firms.
3.21%
Share reduction more than 1.5x AXSM's 7.89%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
3.21%
Diluted share reduction more than 1.5x AXSM's 7.89%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
18.46%
OCF growth above 1.5x AXSM's 3.25%. David Dodd would confirm a clear edge in underlying cash generation.
18.52%
FCF growth above 1.5x AXSM's 2.82%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
80.04%
Positive long-term OCF/share growth while AXSM is negative. John Neff would see a structural advantage in sustained cash generation.
77.11%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
-27.06%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
72.83%
Positive 10Y CAGR while AXSM is negative. John Neff might see a substantial advantage in bottom-line trajectory.
70.62%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
-36.68%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
109.68%
Equity/share CAGR of 109.68% while AXSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-48.78%
Negative 5Y equity/share growth while AXSM is at 20173.50%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-45.28%
Negative 3Y equity/share growth while AXSM is at 185.49%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while AXSM invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-20.44%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-5.39%
We’re deleveraging while AXSM stands at 0.47%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
4.88%
R&D dropping or stable vs. AXSM's 39.77%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-40.17%
We cut SG&A while AXSM invests at 5.39%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.